Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 6Meningioma 6Paraganglioma 5Neuroblastoma 5Pheochromocytoma 4Medulloblastoma 3Carcinoid Tumor 2von Hippel-Lindau Disease 1Somatostatinoma 1Pinealoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroma, Acoustic 1Neuroectodermal Tumors, Primitive 1Neoplasms, Neuroepithelial 1Multiple Endocrine Neoplasia Type 1 1Kidney Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ganglioneuroma 1Ganglioneuroblastoma 1Familial ependymoma 1Ependymoma 1Craniopharyngioma 1Choroid Plexus Neoplasms 1Brain Neoplasms 1

Interventions

pentetreotide 2Magnetic Resonance Spectroscopy 2tipifarnib 1gallium Ga 68 dotatate 1cixutumumab 1Trastuzumab 1Specimen Handling 1Salts 1Oxaliplatin 1Octreotide 1Nivolumab 1Leucovorin 1Ipilimumab 1Floxuridine 1Fentanyl 1Everolimus 1CTLA-4 Antigen 1Acetates 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × gallium Ga 68 dotatate × CNS × Clear all
NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

University of Iowa

Phase 2 Completed
68 enrolled 8 charts
CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡